AGAH, the German Association for Applied Human Pharmacology, held its 25th Annual Meeting on 21-22 April in Berlin, which focused on the topic “Exploratory drug development in immunological therapy”.
The first day’s sessions covered a variety of immunological targets inherently related to the cascade of immune response mechanisms before highlighting the monitoring of immunotoxicity and immunogenicity in novel immunological therapies. The sessions on day 2 began with an overview of early clinical trials with vaccines and then concluded by addressing the various challenges faced in immunotherapy, examining lessons learned in the last 10 years.
The presentations can be accessed at the following link.
AGAH is a founding member of EUFEMED (the European Federation for Exploratory Medicines Development) that was formally incorporated in May 2015 and also includes AHPPI, Club Phase 1, and BAPU – the British, French and Belgian professional member associations specialising in human pharmacology.
Written by John Horkulak, Executive Director, Corporate Development
Celerion, Inc. John is based in Berlin and is a member of AHPPI.